

PHARMACY POLICY STATEMENT

Common Ground Healthcare Cooperative (CGHC)

DRUG NAME	Ztalmy (ganaxolone)
BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Ztalmy is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. Its anticonvulsant effects are thought to result from positive allosteric modulation of the GABA A receptor in the central nervous system. Ztalmy, the first drug specifically for CDD, was approved by the FDA in 2022 and is supplied as a suspension for oral administration three times a day. Dosing is weight based if the patient weighs 28 kg or less.

CDD an X-linked developmental epileptic encephalopathy caused by mutations of the CDKL5 gene that result in nonfunctional or absent CDKL5 protein. It is associated with refractory infantile onset epilepsy, global developmental delay, and variable features that include sleep difficulties, behavioral disturbances, and movement disorders. Epilepsy usually begins in the first 3 months of life. The mutation is more prevalent in females but the course of disease is more severe in males.

Ztalmy (ganaxolone) will be considered for coverage when the following criteria are met:

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

For **initial** authorization:

1. Member is at least 2 years of age; AND
2. Medication must be prescribed by or in consultation with neurologist; AND
3. Member has a documented diagnosis of CDKL5 deficiency confirmed by genetic testing results; AND
4. Member's seizure onset was within the first year of life; AND
5. Motor and cognitive developmental delays are present; AND
6. Documented trial and failure of at least 2 previous anticonvulsants; AND
7. Documentation of monthly seizure frequency on current therapy.
8. **Dosage allowed/Quantity limit:** See prescribing information for starting doses and titration.
 Max dose for weight 28 kg or less: 63mg/kg/day (21 mg/kg TID)
 Max dose for weight greater than 28 kg: 1800 mg/day (600 mg TID)

If all the above requirements are met, the medication will be approved for 3 months.



HEALTHCARE COOPERATIVE

For **reauthorization**:

1. Chart notes must include documentation of a clinically significant reduction of major motor seizure frequency compared to baseline.

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Ztalmly (ganaxolone) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
04/19/2022	New policy for Ztalmly created.

References:

1. Ztalmly [prescribing information]. Marinus Pharmaceuticals, Inc.; 2022.
2. Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder (Marigold). ClinicalTrials.gov Identifier: NCT03572933. Updated November 13, 2020. Accessed April 19, 2022. <https://clinicaltrials.gov/ct2/show/NCT03572933>
3. Olson HE, Daniels CI, Haviland I, et al. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. *J Neurodev Disord.* 2021;13(1):40. Published 2021 Sep 16. doi:10.1186/s11689-021-09384-z
4. Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. *Pediatr Neurol.* 2019;97:18-25. doi:10.1016/j.pediatrneurol.2019.02.015
5. Jakimiec M, Paprocka J, Śmigiel R. CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy. *Brain Sci.* 2020;10(2):107. Published 2020 Feb 17. doi:10.3390/brainsci10020107

Effective date: 01/01/2025

Revised date: 04/19/2022